Jonathan Zalevsky Sells 180 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

robot
Abstract generation in progress

Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares of the company’s stock on February 18th for a total of $13,140, bringing his direct ownership to 21,174 shares. This follows previous sales in January and November. The stock is currently trading near $73.73, and while analysts have a “Moderate Buy” consensus rating with a target of approximately $119.86, Zacks has trimmed some near-term estimates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)